XSpray Pharma AB (publ) logo

XSPRAY - XSpray Pharma AB (publ) Share Price

SEK68 -0.6  -0.9%

Last Trade - 13/09/19

Sector
Healthcare
Size
Small Cap
Market Cap £85.4m
Enterprise Value £72.3m
Revenue £23.1k
Position in Universe 753rd / 1473
Bullish
Bearish
Unlock XSPRAY Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

XSPRAY Revenue Unlock XSPRAY Revenue

Net Income

XSPRAY Net Income Unlock XSPRAY Revenue

Normalised EPS

XSPRAY Normalised EPS Unlock XSPRAY Revenue

PE Ratio Range

XSPRAY PE Ratio Range Unlock XSPRAY Revenue

Dividend Yield Range

XSPRAY Dividend Yield Range Unlock XSPRAY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
XSPRAY EPS Forecasts Unlock XSPRAY Revenue
Profile Summary

XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Public Since September 28, 2017
No. of Shareholders: n/a
No. of Employees: 13
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 15,076,460
Free Float (0.0%)
Eligible for
ISAs
SIPPs
XSPRAY Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for XSPRAY
Upcoming Events for XSPRAY
Wednesday 12th February, 2020 Estimate
Q4 2019 XSpray Pharma AB (publ) Earnings Release
Similar to XSPRAY
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.